Zoetis Inc. (NYSE:ZTS) Holdings Boosted by Fulcrum Capital LLC

Fulcrum Capital LLC increased its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 3.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,546 shares of the company's stock after buying an additional 1,728 shares during the period. Zoetis comprises 1.9% of Fulcrum Capital LLC's portfolio, making the stock its 18th largest holding. Fulcrum Capital LLC's holdings in Zoetis were worth $8,652,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC lifted its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 140 shares in the last quarter. Rakuten Securities Inc. boosted its position in Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares during the period. Navigoe LLC acquired a new stake in Zoetis in the 4th quarter valued at $30,000. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis in the fourth quarter valued at about $44,000. Finally, Asset Planning Inc acquired a new position in shares of Zoetis during the fourth quarter worth about $58,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Down 0.2%

Shares of Zoetis stock traded down $0.39 during trading on Wednesday, reaching $169.91. The company had a trading volume of 917,768 shares, compared to its average volume of 2,524,915. The company has a market cap of $75.65 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The firm's fifty day moving average is $157.04 and its 200-day moving average is $164.43. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the prior year, the business earned $1.38 earnings per share. Zoetis's quarterly revenue was up 1.4% on a year-over-year basis. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio (DPR) is 35.91%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ZTS. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Barclays raised their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Finally, Piper Sandler lifted their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Zoetis presently has an average rating of "Buy" and a consensus target price of $212.75.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at $2,682,770. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Willie M. Reed sold 1,210 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now directly owns 11,245 shares of the company's stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.18% of the stock is owned by insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.